Hejing Biotech announced that the SGT003 injection independently developed by the holding subsidiary Shunjing Pharmaceutical is undergoing phase I/IIa clinical study, and recently completed the enrollment and administration of the first test subjects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.